Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Nestle begins work on ‘companion products’ for weight loss drugs

by Uma
0 comment
2023 10 19T071523Z 2 LYNXMPEJ9I093 RTROPTP 4 NESTLE STOCKS WEGOVY

Nestle begins work on ‘companion products’ for weight loss drugs

By Richa Naidu

LONDON (Reuters) – Nestle on Thursday said it has started work on products to “companion” weight loss drugs like Novo Nordisk’s game-changing Wegovy, hoping to cash in on their growing popularity.

The Swiss food giant’s CEO Mark Schneider said Nestle had not seen any impact from such drugs on sales so far, referring to the threat they pose to the packaged food industry that has spooked investors in recent weeks.

Nestle shares fell this month after Walmart, the world’s biggest retailer, said it saw a slight pullback in food consumption with people taking appetite-suppressing drugs.

“We’re working already on a wide range of products that could serve as companion products,” Schneider said during an earnings briefing, noting that some supplements can help with the “loss of lean muscle mass” and “rapid regain of weight”.

“The largest parts of our portfolio will not be affected” by this new breed of weight loss drugs, he said.

Globally, Nestle’s biggest businesses are coffee and pet care, while frozen food, confectionary and ice cream make up 15% of sales.

“We’re watching this carefully and will keep you updated,” Schneider said.

Wegovy has been shown to help patients reduce body weight by around 15% when used along with exercise and lifestyle changes. It is so far available in the United States, Norway, Denmark and, as of late July, Germany.

 

(Reporting by Richa Naidu; Editing by Christopher Cushing)